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BACKGROUND Percutaneous coronary intervention (PCI) with drug
eluting stent (DES) in small vessel coronary disease
(diameter <2.8 mm) has been proved superior to plain balloon an-
gioplasty or bare metal stent with lower target lesion revasculariza-
tion (TLR) rate. Drug coated balloon (DCB) has been used to treat
de-novo small vessel coronary disease (SVD) with promising result
and shorter dual antiplatelet therapy (DAPT) duration. The purpose of
the study is to compare the safety and effectiveness of DCB in de novo
SVD compared to second generation DES at 1 year.
METHODS We reviewed 3613 angioplasty cases retrospectively from
2011 to 2013 and identiﬁed 335 patients with SVD treated with device
diameter  2.5 mm. 172 were treated with DCB only (paclitaxel-pac-
cocath) and 163 patients treated with second generation DES (ever-
olimus 33.7%, zotarolimus 33.7% and biolimus 32.5%) with clinical
follow up at 12 months.
RESULTS There was no difference in gender (male 76.7% vs 71.8%,
p ¼ 0.32), age (mean 61.0 vs 61.2, p ¼ 0.35), incidence of diabetes
(51.2% vs 49.1%, p ¼ 0.74), hypertension (72.7% vs 69.3%, p ¼ 0.55),
hyperlipidemia (69.8% vs 72.4, p ¼ 0.63), and smoker (45.4% vs
46.6%, p ¼ 0.83). DCB patients had smaller reference vessel diameter
(2.22  0.29 vs 2.43  0.19 mm, p < 0.001), and received smaller de-
vices (diameter 2.28  0.21 vs 2.38  0.12 mm, p < 0.001; length 20.2 
6.0 vs 22.2  7.2 mm, p < 0.005) compared to the DES group. There
was no signiﬁcant difference on number of devices used (1.37  0.6 vs
1.39  0.7, p ¼ 0.25) or the distribution of type C lesion (42.44% vs
37.79%, p ¼ 0.66) between the DCB and DES arms. There was a trend
towards larger acute lumen gain in the DES treated vessels (1.70 
0.48 mm) compared to DCB (1.00  0.53, p ¼ 0.09). There were more
patients presenting with acute coronary syndrome (ACS) in the DCB
group (77.9% vs 62.2%, p < 0.005). Despite that, patients treated with
DCB received shorter duration of dual antiplatelet therapy (DAPT; 7.4
 4.7 months vs 11.8  1.4 months, p < 0.001). Cumulative one-year
events showed no difference in composite major adverse cardiac
events (MACE) (11.6% vs 11.7%), p ¼ 1.00), death (1.7% vs 3.7%, p ¼
0.33), myocardial infarction (5.8% vs 8.6%, p ¼ 0.40), target lesion
revascularization (5.2% vs 3.68%, p ¼ 0.60) and stroke events (1.16%
vs 0.61%, p ¼ 1.00) between the DCB and DES arms respectively.
Univariate, followed by multivariate cox-regression analysis to all risk
factors and lesion characteristics revealed type C lesion as the only
independent predictor of 1-year composite MACE (RR 2.52, p
value < 0.05).
CONCLUSIONS In this high risk cohort of patients (>50% diabetics,
78% ACS) DCB only angioplasty delivered good clinical outcome at 1
year. The result was comparable to those treated with modern DES but
has the added beneﬁt of a shorter DAPT regime.
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BACKGROUND Second-generation drug-coated balloons (DCB) may
be an alternative to stents in selected populations for the treatment of
native coronary lesions. However, the use of these devices may be
hampered by a certain risk of acute vessel recoil or residual coronary
dissection. Moreover, stenting after DCB has limited scientiﬁc evi-
dence. Little is known when a not ﬂow-limiting dissection is left after
DCB-angioplasty.
METHODS This was a prospective observational study whose aim was
to investigate the outcome of a consecutive series of patients with
native coronary artery disease treated with second-generation DCB
and residual coronary dissection at two Italian centers. We evaluated
patient clinical conditions at 1 and 9 months and angiographic follow
up was undertaken at 6 months.RESULTS Between July 2012 and July 2014, 156 patients were treated
with DCB for native coronary artery disease. Fifty-two patients had a
ﬁnal dissection, 4 of which underwent prosthesis implantation and 48
were left untreated and underwent angiographic follow up after 201
days (I.Q. range: 161-250 days). The dissections were all type A-C and
none determined an impaired distal ﬂow. Complete vessel healing at
angiography was observed in 45 patients (93.8%), whereas 3 patients
had persistent but uncomplicated dissections, and 3 binary restenosis
(6.2%). Late-lumen-loss was 0.14mm (-0.14-0.42). Major adverse car-
diovascular events occurred in 11 patients of the entire cohort and in 4
of the dissection cohort (7.2% vs. 8.1%, p¼0.48). We observed 8 and 3
target-lesion revascularizations respectively (5.3% vs. 6.2%, p¼0.37).
CONCLUSIONS In this cohort of consecutive patients treated with
new-generation DCB and left with a ﬁnal dissection, this strategy of
revascularization seemed associated with the sealing of most of dis-
sections and without signiﬁcant neo-intimal hyperplasia.
CATEGORIES CORONARY: Drug-Eluting Balloons and Local Drug
Delivery
KEYWORDS Dissection, Drug-eluting balloon
TCT-410
Results Of Percutaneous Coronary Intervention Of “De Novo” Lesions With
Sequent Please Paclitaxel Eluting Balloon Catheter At A Very Long-Term
Follow-Up
Ignacio Sanchez-Perez,1 Alfonso Jurado-Roman,2 Fernando Lozano,1
Natalia Pinilla-Echeverri,3 Maria T. Lopez-Lluva,4
Manuel Marina-Breysse,5 Andrea Moreno-Arciniegas6
1Hospital General Universitario de Ciudad Real, Ciudad Real, Castilla-
La Mancha; 2Hospital General Universitario de Ciudad Real, Ciudad
Real, Spain; 3McMaster University / Hamilton General Hospital,
Hamilton, Ontario; 4Hospital General Universitario de Ciudad Real.
Servicio de Hemodinámica, Ciudad Real, Castilla la Mancha;
5University General Hospital of Ciudad Real, Ciudad Real, Castilla la
Mancha, Spain; 6Hospital General Universitario de Ciudad Real, Ciudad
Real, Castilla La Mancha
BACKGROUND Drug eluting balloons currently constitute one of the
therapeutic tools used in percutaneous coronary intervention (PCI) of
de novo coronary lesions, mainly in bifurcations and small vessels.
Nowadays, their results at a very long-term follow up are unclear. The
main objective of this study was to evaluate the efﬁcacy and safety of
second-generation Sequent Please paclitaxel eluting balloon (PEB) in
de novo coronary lesions at 6 years.
METHODS We prospectively included 87 consecutive patients (6912
years, 66.7% male) with 87 de novo lesions treated with PEB between
March 2009 and January 2014. Additional bare metal stent (BMS) or
drug-eluting stent (DES) was implanted after PEB if the result was not
satisfactory because of dissection, recoil or signiﬁcant residual ste-
nosis. We evaluated the presence of major cardiac events (MACE) after
a prolonged clinical follow-up (median 51 months): death, nonfatal
myocardial infarction, target lesion revascularization (TLR) and
thrombosis.
